These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6177593)

  • 21. [Components of the fibrinolytic system of Guerin's epithelioma].
    Zurawski P; Zagórska M; Grygoruk M; Worowski K
    Acta Haematol Pol; 1985; 16(3-4):151-7. PubMed ID: 3835771
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of hepatectomy on the posttraumatic fibrinolysis inhibition and the primary fibrinolysis inhibitor in the rat.
    Högstorp H; Jacobsson H; Saldeen T
    Thromb Res; 1980 May 1-15; 18(3-4):361-8. PubMed ID: 7191149
    [No Abstract]   [Full Text] [Related]  

  • 23. RGDFAP: platelet aggregation inhibitory and profibrinolytic hybrid peptide (RGDF coupled with the carboxy terminal part of alpha 2-antiplasmin) enhances plasminogen binding to platelets.
    Udvardy M; Schwartzott D; Jackson K; Posan E; Rak K; McKee PA
    Blood Coagul Fibrinolysis; 1995 Jul; 6(5):481-5. PubMed ID: 8589217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
    Moreno JA; Gálvez MM; Cornudella R; Angós JA; Romero MS; Gutiérrez M
    Sangre (Barc); 1994 Apr; 39(2):111-6. PubMed ID: 8059288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of anterior chamber fibrinolysis.
    O'Rourke J; Moore M; Kreutzer DL
    Curr Eye Res; 1985 May; 4(5):569-78. PubMed ID: 2410195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
    Wu JH; Diamond SL
    Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The response of the fibrinolytic system in trauma.
    Risberg B
    Acta Chir Scand Suppl; 1985; 522():245-71. PubMed ID: 3893000
    [No Abstract]   [Full Text] [Related]  

  • 29. [Relation between the fibrinolytic activity of the blood, placenta and fetal membranes in normal and complicated pregnancy].
    Kuznik BI; Zagorodniaia ED; Khyshova DR
    Akush Ginekol (Mosk); 1983 Oct; (10):14-6. PubMed ID: 6686414
    [No Abstract]   [Full Text] [Related]  

  • 30. Fibrinolysis inhibition after a major standardized trauma.
    Bagge L; Carlin G; Hjelmstedt A; Högstorp H; Jacobsson H; Modig J; Saldeen T
    Ups J Med Sci; 1982; 87(1):55-66. PubMed ID: 6181600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance.
    Carpenter SL; Mathew P
    Haemophilia; 2008 Nov; 14(6):1250-4. PubMed ID: 19141165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Intensification of the effect of exogenous plasminogen activators on lysis of fibrin blood clots due to a decrease in the level of alpha-2- antiplasmin by a plasmasorption method].
    Ogloblina OG; Saburova OS; Semenova OA; Belova LA
    Biokhimiia; 1994 Jan; 59(1):62-8. PubMed ID: 7509643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of L-asparaginase therapy on the fibrinolytic system.
    Vellenga E; Kluft C; Mulder NH; Wijngaards G; Nieweg HO
    Br J Haematol; 1984 Jun; 57(2):247-54. PubMed ID: 6203549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of inhibitors with chromogenic substrates.
    Latallo ZS
    J Clin Pathol Suppl (R Coll Pathol); 1980; 14():48-9. PubMed ID: 6159376
    [No Abstract]   [Full Text] [Related]  

  • 35. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture.
    Collen D
    Thromb Haemost; 1980 Jun; 43(2):77-89. PubMed ID: 6450468
    [No Abstract]   [Full Text] [Related]  

  • 36. Fibrinolytic inhibitor in type II hyperlipoproteinaemia.
    Brommer EJ; Gevers Leuven JA; Kluft C; Wingaards G
    Lancet; 1982 May; 1(8280):1066. PubMed ID: 6122864
    [No Abstract]   [Full Text] [Related]  

  • 37. Monitoring of fibrinolytic treatment with chromogenic substrate assays.
    Juhan-Vague I; Aillaud MF; Chiche G
    Acta Chir Scand Suppl; 1982; 509():125-8. PubMed ID: 6962615
    [No Abstract]   [Full Text] [Related]  

  • 38. Plasma antiplasmin activities in experimental lung insufficiency.
    Aasen AO; Saugstad OD; Lium B; Guldvog I; Lyngaas K; Larsbraaten M; Amundsen E
    Acta Chir Scand Suppl; 1980; 499():113-21. PubMed ID: 6935891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Appropriate milieu for the assay of alpha-2-antiplasmin activity with chromogenic substrates.
    Kluft C; Wijngaards G; Jie AF; Groeneveld E
    Haemostasis; 1985; 15(3):198-203. PubMed ID: 3161809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.